We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

1 hedge funds and large institutions have $96 invested in CytoMed Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$106

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$96 +$106 +61 New

GDTC Hedge Fund Activity: Q3 2024 in Review

1 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q3 2024, worth a combined $96.

Buyers outnumbered sellers: 1 fund opened new GDTC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $106.

  • 1 institutional investor held CytoMed Therapeutics (GDTC) as of Q3 2024, up from 0 in Q2 2024.
  • Funds reported $96 of CytoMed Therapeutics stock for Q3 2024.
  • 1 fund opened new CytoMed Therapeutics positions in Q3 2024 and 0 closed out, a net change of +1 holder.
  • The largest CytoMed Therapeutics buyer in Q3 2024 was UBS Group, an estimated $106 added.

Based on aggregated 13F filings for Q3 2024.